Metastatic Rhabdomyosarcoma: Results of a single center in Russia
Abstract
Introduction: Metastatic Rhabdomyosarcoma (RMS) has a poor prognosis despite multimodal therapy. The aim of the study – analyze the results of therapy of metastatic RMS in children treated in the national center in RF.
Methodology: 181 included (<18 years) prospectively enrolled (02.2012 – 12.2019). 159 received program therapy according to the CWS Group guidance, version 2009. 47 (30%) had metastatic disease at presentation and were included.
Results: Median age at diagnosis – 46.93 months (1.5 – 196.2). The age distribution: <1 (n=1; 2%), 1-9 (n=35; 75%), >10 (n=11; 23%). Male to female – 1:0.7. Histopathologic types: embryonal (n=18; 38%), alveolar (n=29; 62%). FP-alveolar RMS by FISH – 19/29 (66%). 43/47 had T2. Initial surgery: biopsy in 34/47 (72%) (primary tumor-27, metastases-7), surgery 13/47 (28%) (R1-4, R2-9). Сhemotherapy: CEVAIE (n=28; 60%), CEVAIE/other (n=17; 36%), other (n=2; 4%). Local control of the primary tumor – 46/47: only surgery 11/46 (24%), only radiotherapy 12/46 (26%), surgery and RT 23/46 (50%).
The best second-look surgery of the primary tumor: R0 (n=8), R1 (n=15), R2 (n=1). Regional lymph node dissection – 8/27 (30%). Local control of distant metastases – 11/47 (23%). Maintenance treatment – 37/47 (79%): O-TI/E (n=12), CYC/VNL (n=25). Median follow-up time: 53.93 months (1.10–139.9). 23 alive, 24 dead. 5-year EFS and OS: 42,1% (±7,2%; 95% Cl), 51% (±7,2%; 95% Cl).
Patients with ≤ 2 ORFs (n=35; 74%) had better outcome than those with ≥ 3 ORFs (n=12; 26%): 5-year EFS was 56% versus 8.3% (p<.07), 5-year OS was 63% versus 17% (p<.001). Number of sites of metastatic disease (p<.01) and bone or bone morrow involvement (p<.004) were correlated with worse EFS/OS. Patients with FN alveolar RMS had a better outcome with 5-year EFS/OS (66%/70%), compared to patients with embryonal RMS (55%/66%), FP-alveolar RMS (21/26%) (p<.06).
Conclusions: Multimodal therapy improved the outcome of metastatic RMS. ORFs and fusion status were predictive for OS.
How to Cite
Stradomskaia T, Grachev N, Nechesnyuk A, Bolshakov N, Talypov S, Shamanskaya T, et al. Metastatic Rhabdomyosarcoma: Results of a single center in Russia. OncoDaily Med J. 2025. doi:10.69690/ODMJ-018-0425-655